Treatment of residual disease following neoadjuvant therapy in breast cancer-Reference-Cited by-同舟云学术

Treatment of residual disease following neoadjuvant therapy in breast cancer

Published:2023-11-22 Issue:1 Volume:129 Page:18-25
ISSN:0022-4790
Container-title:Journal of Surgical Oncology
language:en
Short-container-title:Journal of Surgical Oncology

Author:

Heater Natalie K.¹^ORCID,Somayaji Khyati¹,Gradishar William¹²

Affiliation:

1. Department of Medicine McGaw Medical Center of Northwestern University Chicago Illinois USA

2. Robert H. Lurie Comprehensive Cancer Center of Northwestern University Chicago Illinois USA

Abstract

AbstractSubstantial advances have been made in the systemic treatment of breast cancer with residual disease following neoadjuvant therapy. We reviewed recent and ongoing studies informing the standard clinical management of residual disease by subtype: HER2+, TNBC, and HR+/HER2‐, as well as strategies for BRCA+ disease. We conclude with a discussion of ongoing clinical trials and current controversies regarding the treatment of residual disease in breast cancer.

Publisher

Wiley

Subject

Oncology,General Medicine,Surgery

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jso.27523

Reference49 articles.

1. Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline

2. MD Anderson Cancer Center. 2023. Residual Cancer Burden Calculator.https://www3.mdanderson.org/app/medcalc/index.cfm?pagename=jsconvert3

3. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients

4. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

5. Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Navigating axillary staging post-neoadjuvant systemic therapy: innovations, efficacy, and oncologic safety;Gland Surgery;2024-06

2. Navigating the complexity of post‐NAT therapy in breast cancer: The role of ctDNA testing;Journal of Surgical Oncology;2024-04-23